156 related articles for article (PubMed ID: 26956920)
61. Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation.
Chen Y; Quan P; Liu X; Guo W; Song W; Cun D; Wang Z; Fang L
J Pharm Pharmacol; 2015 Sep; 67(9):1232-9. PubMed ID: 25994482
[TBL] [Abstract][Full Text] [Related]
62. Flavosomes, novel deformable liposomes for the co-delivery of anti-inflammatory compounds to skin.
Zhang ZJ; Michniak-Kohn B
Int J Pharm; 2020 Jul; 585():119500. PubMed ID: 32512226
[TBL] [Abstract][Full Text] [Related]
63. Enhanced transdermal delivery of luteolin via non-ionic surfactant-based vesicle: quality evaluation and anti-arthritic assessment.
Abidin L; Mujeeb M; Imam SS; Aqil M; Khurana D
Drug Deliv; 2016; 23(3):1079-84. PubMed ID: 25116512
[TBL] [Abstract][Full Text] [Related]
64. Effect of lipid molecule headgroup mismatch on non steroidal anti-inflammatory drugs induced membrane fusion.
Mondal Roy S; Sarkar M
Langmuir; 2011 Dec; 27(24):15054-64. PubMed ID: 21999838
[TBL] [Abstract][Full Text] [Related]
65. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.
Shende PK; Gaud RS; Bakal R; Patil D
Colloids Surf B Biointerfaces; 2015 Dec; 136():105-10. PubMed ID: 26364091
[TBL] [Abstract][Full Text] [Related]
66. Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet.
Srivastava R; Kumar D; Pathak K
Int J Pharm; 2012 May; 427(2):153-62. PubMed ID: 22306039
[TBL] [Abstract][Full Text] [Related]
67. Low-dose meloxicam (Vivlodex) for osteoarthritis pain.
Med Lett Drugs Ther; 2016 Mar; 58(1490):35-6. PubMed ID: 26963155
[No Abstract] [Full Text] [Related]
68. Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats.
Gunew MN; Menrath VH; Marshall RD
J Feline Med Surg; 2008 Jul; 10(3):235-41. PubMed ID: 18440263
[TBL] [Abstract][Full Text] [Related]
69. The pharmacokinetics of meloxicam in vultures.
Naidoo V; Wolter K; Cromarty AD; Bartels P; Bekker L; McGaw L; Taggart MA; Cuthbert R; Swan GE
J Vet Pharmacol Ther; 2008 Apr; 31(2):128-34. PubMed ID: 18307504
[TBL] [Abstract][Full Text] [Related]
70. Pharmacokinetics and safety of oral administration of meloxicam to foals.
Raidal SL; Edwards S; Pippia J; Boston R; Noble GK
J Vet Intern Med; 2013; 27(2):300-7. PubMed ID: 23425143
[TBL] [Abstract][Full Text] [Related]
71. Topical and cutaneous delivery using nanosystems.
Roberts MS; Mohammed Y; Pastore MN; Namjoshi S; Yousef S; Alinaghi A; Haridass IN; Abd E; Leite-Silva VR; Benson H; Grice JE
J Control Release; 2017 Feb; 247():86-105. PubMed ID: 28024914
[TBL] [Abstract][Full Text] [Related]
72. Cutaneous delivery of natural antioxidants: the enhancement approaches.
Aljuffali IA; Hsu CY; Lin YK; Fang JY
Curr Pharm Des; 2015; 21(20):2745-57. PubMed ID: 25925121
[TBL] [Abstract][Full Text] [Related]
73. Single and multiple-dose pharmacokinetics of meloxicam after oral administration to the rabbit (Oryctolagus cuniculus).
Carpenter JW; Pollock CG; Koch DE; Hunter RP
J Zoo Wildl Med; 2009 Dec; 40(4):601-6. PubMed ID: 20063804
[TBL] [Abstract][Full Text] [Related]
74. Pharmacokinetics of intravenous and oral meloxicam in ruminant calves.
Coetzee JF; KuKanich B; Mosher R; Allen PS
Vet Ther; 2009; 10(4):E1-8. PubMed ID: 20425727
[TBL] [Abstract][Full Text] [Related]
75. Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation.
Weyna DR; Cheney ML; Shan N; Hanna M; Zaworotko MJ; Sava V; Song S; Sanchez-Ramos JR
Mol Pharm; 2012 Jul; 9(7):2094-102. PubMed ID: 22642304
[TBL] [Abstract][Full Text] [Related]
76. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.
Şengel-Türk CT; Hasçiçek C; Dogan AL; Esendagli G; Guc D; Gönül N
Drug Dev Ind Pharm; 2012 Sep; 38(9):1107-16. PubMed ID: 22348284
[TBL] [Abstract][Full Text] [Related]
77. [Transdermal Delivery of NSAIDs].
Nakajima T; Makino K
Masui; 2015 Nov; 64(11):1141-4. PubMed ID: 26689064
[TBL] [Abstract][Full Text] [Related]
78. Cytotoxicity testing of carrier-based microcomposites for DPI application.
Ambrus R; Pomázi A; Réti-Nagy K; Fenyvesi F; Vecsernyés M; Szabó-Révész P
Pharmazie; 2011 Jul; 66(7):549-50. PubMed ID: 21812334
[TBL] [Abstract][Full Text] [Related]
79. Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations.
Di Salvo A; Giorgi M; Catanzaro A; Deli G; della Rocca G
J Vet Pharmacol Ther; 2016 Feb; 39(1):102-5. PubMed ID: 26789011
[TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration.
Lai OR; Di Bello A; Soloperto S; Freggi D; Marzano G; Cavaliere L; Crescenzo G
J Wildl Dis; 2015 Apr; 51(2):509-12. PubMed ID: 25647596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
